Company / Shareholders' Equity
TEVA PHARMACEUTICAL INDUSTRIES LTD Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$7.9B
FY2025
5-year range
$5.4B / $10.3B
FY2021-FY2025
Trend
+47.2%
vs FY2024
Sector context
#15 of 213
Health Care
What the data says
Among 213 Health Care companies, TEVA PHARMACEUTICAL INDUSTRIES LTD is in the top 7% for shareholders' equity. Shareholders' Equity returned to growth in FY2025 after 3 years of decline, reaching $7.9B.
Based on SEC 10-K filings.
$7.9B in FY2025 with a 5-year CAGR of -4.6%. Top quartile in the Health Care sector.
Improved from $7.5B to $7.9B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +0.5%
- 5-Year CAGR
- -4.6%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 213This company $7.9B Sector average $2.5B
▼
+210.4% above sector average
Key checks
Key Insights
- 5-year CAGR of -4.6%, indicating a declining trend.
- In FY2025, shareholders' equity increased 47.2% year-over-year.
- Ranks #15 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.9B | +47.2% |
| FY2024 | $5.4B | -28.4% |
| FY2023 | $7.5B | -3.8% |
| FY2022 | $7.8B | -24.1% |
| FY2021 | $10.3B | +2.5% |
| FY2020 | $10.0B | -28.2% |
| FY2019 | $14.0B | -5.0% |
| FY2018 | $14.7B | -21.5% |
| FY2017 | $18.7B | -46.4% |
| FY2016 | $35.0B | +16.9% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026